Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Otezla (apremilast by Year
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%) (%)
Amgen Otezla (apremilast: 3.0% in FY2025, unchanged from a year earlier.
Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
3.0% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“Sales increased 7% for the full year, primarily driven by 3% volume growth and 2% favorable ch anges to estimated sales deductions.”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.0% | 0.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 3.0% | +1.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 2.0% | -5.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 7.0% | -1.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 8.0% | – | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
Cite this data
StockData. (2026). Amgen Otezla (apremilast (%), annual FY2021–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-otezla-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.